Protein-protein interactions and dopamine D2 receptor signaling: A calcium connection

Molecular Pharmacology

Volumn 74, Issue 2, 2008, Pages 317-319

  Stanwood, Gregg D ^a  

^a VANDERBILT UNIVERSITY MEDICAL CENTER   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ADENYLATE CYCLASE; CALCIUM BINDING PROTEIN; DOPAMINE 2 RECEPTOR; DOPAMINE 3 RECEPTOR; DOPAMINE 4 RECEPTOR; G PROTEIN COUPLED RECEPTOR; MITOGEN ACTIVATED PROTEIN KINASE; PROTEIN S100B; SEROTONIN RECEPTOR;

BACTERIUM; BIOASSAY; BIOPHYSICS; BLOOD BRAIN BARRIER; BRAIN DEVELOPMENT; BRAIN LEVEL; CELL ACTIVITY; CELL STRAIN HEK293; CYTOPLASM; DEPRESSION; DISEASE ASSOCIATION; ENZYME ACTIVATION; ENZYME INHIBITION; FEEDBACK SYSTEM; HUMAN; IMMUNOHISTOCHEMISTRY; IN VITRO STUDY; IN VIVO STUDY; MEDIATOR; MODULATION; MOLECULAR DYNAMICS; NEUROTRANSMISSION; PRIORITY JOURNAL; PROTEIN BINDING; PROTEIN EXPRESSION; PROTEIN FUNCTION; PROTEIN LOCALIZATION; PROTEIN PROTEIN INTERACTION; RECEPTOR UPREGULATION; REVIEW; SCHIZOPHRENIA; SIGNAL TRANSDUCTION; TRAUMATIC BRAIN INJURY; TWO HYBRID SYSTEM;

ANIMALS; CALCIUM; HUMANS; PROTEIN BINDING; PROTEIN INTERACTION MAPPING; RECEPTORS, DOPAMINE D2; SIGNAL TRANSDUCTION;

EID: 47949094350     PISSN: 0026895X     EISSN: 15210111     Source Type: Journal    
DOI: 10.1124/mol.108.049098     Document Type: Review

References (32)

1. Arnsten AF and Li BM (2005) Neurobiology of executive functions: catecholamine influences on prefrontal cortical functions. Biol Psychiatry 57:1377-1384.
2. Azmitia EC (2001) Neuronal instability: implications for Rett's syndrome. Brain Dev 23 (Suppl 1):S1-S10.
3. Beaulieu JM, Sotnikova TD, Marion S, Lefkowitz RJ, Gainetdinov RR, and Caron MG (2005) An Akt/beta-arrestin 2/PP2A signaling complex mediates dopaminergic neurotransmission and behavior. Cell 122:261-273.
4. Beaulieu JM, Tirotta E, Sotnikova TD, Masri B, Salahpour A, Gainetdinov RR, Borrelli E, and Caron MG (2007) Regulation of Akt signaling by D2 and D3 dopamine receptors in vivo. J Neurosci 27:881-885.
5. Biederman J and Faraone SV (2005) Attention-deficit hyperactivity disorder. Lancet 366:237-248.
6. Binda AV, Kabbani N, Lin R, and Levenson R (2002) D2 and D3 dopamine receptor cell surface localization mediated by interaction with protein 4.1N. Mol Pharmacol 62:507-513.
7. Bockaert J, Fagni L, Dumuis A, and Marin P (2004) GPCR interacting proteins (GIP). Pharmacol Ther 103:203-221.
8. Free RB, Hazelwood LA, Cabrera DM, Spalding HN, Namkung Y, Rankin ML, and Sibley DR (2007) D1 and D2 dopamine receptor expression is regulated by direct interaction with the chaperone protein calnexin. J Biol Chem 282:21285-21300.
9. Fuxe K, Ferre S, Canals M, Torvinen M, Terasmaa A, Marcellino D, Goldberg SR, Staines W, Jacobsen KX, Lluis C, Woods AS, Agnati LF, and Franco R (2005) Adenosine A2A and dopamine D2 heteromeric receptor complexes and their function. J Mol Neurosci 26:209-220.
10. Girault JA and Greengard P (2004) The neurobiology of dopamine signaling. Arch Neurol 61:641-644.
11. Goldman-Rakic PS (1998) The cortical dopamine system: role in memory and cognition. Adv Pharmacol 42:707-711.
12. Kabbani N and Levenson R (2007) A proteomic approach to receptor signaling: molecular mechanisms and therapeutic implications derived from discovery of the dopamine D2 receptor signalplex. Eur J Pharmacol 572:83-93.
13. Kalivas PW and Volkow ND (2005) The neural basis of addiction: a pathology of motivation and choice. Am J Psychiatry 162:1403-1413.
14. 2 dopamine receptor expression and trafficking is regulated through direct interactions with ZIP. J Neurochem, in press.
15. Kiyatkin EA(1995) Functional significance of mesolimbic dopamine. Neurosci Biobehav Rev 19:573-598.
16. Kleindienst A, Hesse F, Bullock MR, and Buchfelder M (2007) The neurotrophic protein S100B: value as a marker of brain damage and possible therapeutic implications. Prog Brain Res 161:317-325.
17. Lachowicz JE and Sibley DR (1997) Molecular characteristics of mammalian dopamine receptors. Pharmacol Toxicol 81:105-113.
18. Liu XY, Chu XP, Mao LM, Wang M, Lan HX, Li MH, Zhang GC, Parelkar NK, Fibuch EE, Haines M, Neve KA, Liu F, Xiong ZG, and Wang JQ (2006) Modulation of D2R-NR2B interactions in response to cocaine. Neuron 52:897-909.
19. Liu Y, Buck DC, Macey TA, Lan H, and Neve KA (2007) Evidence that calmodulin binding to the dopamine D2 receptor enhances receptor signaling. J Recept Signal Transduct Res 27:47-65.
20. 2 receptor function. Mol Pharmacol 74:371-378.
21. Macey TA, Gurevich VV, and Neve KA (2004) Preferential interaction between the dopamine D2 receptor and Arrestin2 in neostriatal neurons. Mol Pharmacol 66: 1635-1642.
22. Missale C, Nash SR, Robinson SW, Jaber M, and Caron MG (1998) Dopamine receptors: from structure to function. Physiol Rev 78:189-225.
23. Negyessy L and Goldman-Rakic PS (2005) Subcellular localization of the dopamine D2 receptor and coexistence with the calcium-binding protein neuronal calcium sensor-1 in the primate prefrontal cortex. J Comp Neurol 488:464-475.
24. Nestler EJ (2001) Neurobiology. Total recall - the memory of addiction. Science 292:2266-2267.
25. Neve KA, Seamans JK, and Trantham-Davidson H (2004) Dopamine receptor signaling. J Recept Signal Transduct Res 24:165-205.
26. Rashid AJ, So CH, Kong MM, Furtak T, El-Ghundi M, Cheng R, O'Dowd BF, and George SR (2007) D1-D2 dopamine receptor heterooligomers with unique pharmacology are coupled to rapid activation of Gq/11 in the striatum. Proc Natl Acad Sci U S A 104:654-659.
27. Rothermundt M, Ponath G, and Arolt V (2004) S100B in schizophrenic psychosis. Int Rev Neurobiol 59:445-470.
28. Sen J and Belli A (2007) S100B in neuropathologic states: the CRP of the brain? J Neurosci Res 85:1373-1380.
29. Smith FD, Oxford GS, and Milgram SL (1999) Association of the D2 dopamine receptor third cytoplasmic loop with spinophilin, a protein phosphatase-1-interacting protein. J Biol Chem 274:19894-19900.
30. So CH, Varghese G, Curley KJ, Kong MM, Alijaniaram M, Ji X, Nguyen T, O'Dowd BF, and George SR (2005) D1 and D2 dopamine receptors form heterooligomers and cointernalize after selective activation of either receptor. Mol Pharmacol 68:568-578.
31. Svenningsson P, Chergui K, Rachleff I, Flajolet M, Zhang X, El Yacoubi M, Vaugeois JM, Nomikos GG, and Greengard P (2006) Alterations in 5-HT1B receptor function by p11 in depression-like states. Science 311:77-80.
32. Wainwright MS, Craft JM, Griffin WS, Marks A, Pineda J, Padgett KR, and Van Eldik LJ (2004) Increased susceptibility of S100B transgenic mice to perinatal hypoxia-ischemia. Ann Neurol 56:61-67.